The Role of MicroRNA-133 in Cardiac Hypertrophy Uncovered
2010; Lippincott Williams & Wilkins; Volume: 106; Issue: 1 Linguagem: Inglês
10.1161/circresaha.109.212183
ISSN1524-4571
Autores Tópico(s)Extracellular vesicles in disease
ResumoHomeCirculation ResearchVol. 106, No. 1The Role of MicroRNA-133 in Cardiac Hypertrophy Uncovered Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBThe Role of MicroRNA-133 in Cardiac Hypertrophy Uncovered Maha Abdellatif Maha AbdellatifMaha Abdellatif From the Cardiovascular Research Institute, Department of Cell Biology and Molecular Medicine, University of Medicine and Dentistry of New Jersey, Newark. Originally published8 Jan 2010https://doi.org/10.1161/CIRCRESAHA.109.212183Circulation Research. 2010;106:16–18Studies of microRNAs (miRNAs) have recently uncovered a new level of intricacy in the regulation of gene expression during organogenesis and pathogenesis.1 miR-133, which is enriched in cardiac and skeletal muscle, is involved in cell specification,2 differentiation,3 and development.4 It is also downregulated during cardiac hypertrophy,5–7 which suggested that it may play a role in the underlying pathogenesis. Studies that included targeted deletion, overexpression, and antisense-specific knockdown of miR-133 have unraveled many aspects of its function and targets but have not directly revealed its role in the development of pressure overload–induced hypertrophy. In particular, targeted deletion of miR-133a-1 or miR-133a-2, each of which resulted in ≈50% reduction in cardiac miR-133, equivalent to the decrease associated with cardiac hypertrophy, exhibited no cardiac growth or functional abnormalities under normal or pressure overload conditions.4 On the other hand, complete ablation of miR-133 via double knockout resulted in aberrant proliferation and apoptosis of myocytes, cardiac defects, and prevalent embryonic lethality, whereas those that escaped the lethal phenotype ended with severe cardiac dilatation, but no myocyte hypertrophy.4 In contrast, knockdown of miR-133 via antisense targeting was sufficient for inducing cardiac hypertrophy and reinduction of the fetal gene program in the adult mouse heart.6 The discrepancy between the outcomes could be explained by the different onsets of miR-133 knockdown in the heart. However, none of the studies investigated the relevance of the decrease in miR-133 in the context of pressure overload hypertrophy.It should be noted that whereas overexpression or knockout of a gene in a normal cell can provide invaluable insight regarding its function, normalizing its levels during a specific pathological condition is requisite for obtaining direct evidence regarding its role in the underlying pathogenesis. Indeed, adopting this approach was one of the advantages of the study by Matkovich et al that is reported in this issue, in which they generated a transgenic mouse model overexpressing an α-myosin heavy chain-regulated miR-133 gene.8 In contrast to a β-myosin heavy chain-driven miR-133,4 these animals survived with no abnormalities other than a modest prolongation of the QT interval. The lack of more severe aberrations, which may have been expected from the suppression of some of the validated targets of miR-133 (Table), could be explained by the possibility that miR-133 under normal conditions is saturating with respect to some of its target mRNAs. However, the function of miR-133 was exposed after applying pressure overload to the miR-133 transgenic heart, a situation in which the overexpressed transgene compensated for the reduction in endogenous miR-133. Although cardiac weight was not normalized as a result of this intervention, other aspects of hypertrophy (including apoptosis, fibrosis, and the downregulation of IKr) were restored to baseline levels, whereas the decline in Ito,f and prolongation of QT interval were partly reversed. The decrease in fibrosis in the transgenic mouse could not be explained by suppression of connective tissue growth factor, which is a validated miR-133 target in cardiac myocytes and fibroblasts9; it is most likely a consequence of reduced myocyte dropout, infiltration, fibroblast proliferation, and collagen deposition. Accordingly, this was associated with less ventricular stiffness and lower left ventricular end-diastolic pressure. One shortcoming of the study, though, is that the miR-133 targets that mediates its antiapoptotic function remain to be identified, because the authors excluded the previously validated caspase-9,10 serum response factor, and cyclin D24 targets in the heart. Table 1. Validated miR-133 TargetsTissue or Cell TypeTargetReference*The target was confirmed by miRNA-dependent inhibition of the endogenous protein in the heart or cardiac myocytes and by the luciferase reporter assay in 239 HEK or Cos cells.Cardiac myocytesRas homolog gene family, member A (RhoA)6Cardiac myocytesCell division cycle 42 (Cdc42)6Heart/293HEK cells*Ether-a-go-go-related potassium channel (HERG)12Heart/293HEK cells*Hyperpolarization activated cyclic nucleotide-gated potassium channel 2 (HCN2)13Heart/Cos-1 cells*Cyclin D24H9c2Caspase-910Cardiac myocytes/Cos*Connective tissue growth factor (CTGF)9C2C12Serum response factor (SRF)3MC3T3Runt related transcription factor 2 (Runx2)14Dopaminergic neuronsPaired-like homeodomain 3 (Pitx3)15ZebrafishTTK family protein kinase (Mps1)16Lung cancer cell lineBCL2-like (BCL2L)17Lung cancer cell lineMyeloid cell leukemia sequence 1 (MCL-1)17One of the intriguing findings of this study is that whereas overexpression of miR-133 reduced the density of Ito,f in the unstressed heart, it prevented any further decline associated with increased pressure overload. This apparent paradox can be explained by the fact the Ito,f accessory subunit, Kcnip2, whose expression was inhibited in the unstressed transgenic heart, is not a direct target of miR-133. Thus, the effect of miR-133 on this protein might have been reversed as a result of the reprogramming of gene expression in the hypertrophied myocytes. This emphasizes the need to explore the functions of miRNAs under different developmental, normal, stressed, and pathological conditions to identify the full range of their effects and their potential for therapeutic targeting. A similar argument applies to the verification of the targets of miRNAs in a particular cell type, because "one for many and many for one" characterizes the relation between miRNAs and their targets. This implies that under different conditions, the effect of a miRNA on a target gene is modulated by other coexisting differentially expressed miRNAs and/or RNA-binding proteins that may target the same gene. This explains why some validated targets cannot be confirmed under different experimental conditions. In addition, variations in a specific miRNA:target mRNA stoichiometry in different cellular backgrounds would inevitably impact the outcome of experimental manipulations of the miRNA level. For example, if miR-133 were saturating relative to any of its target mRNA during normal conditions, overexpressing it would be superfluous and, hence, ineffective. In contrast, a similar manipulation during cardiac hypertrophy, where its endogenous levels are downregulated, is apt to reveal its function, as indeed is demonstrated by the work of Matkovich et al.8 This would also argue for the need to reexamine the levels of caspase-9, serum response factor, and cyclin D2 in the miR-133 transgenic mouse during pressure overload.In conclusion, although reducing miR-133 in a normal adult cell background was sufficient to induce cardiac hypertrophy,6 restoring its levels during pressure overload did not prevent it but did repress apoptosis, fibrosis, and K+ channel remodeling.8 This leads to the conclusion that miR-133 does not play an obligatory role in the mechanism underlying the increase in myocyte size during pathological hypertrophy. However, its downregulation is a prerequisite for the development of apoptosis, fibrosis, and prolongation of the QT interval. The different outcomes that were observed following experimental modulation of miR-133 levels in different settings emphasize the fact that the transcriptome/proteome makeup of the cell influences miRNA functionality.Finally, although we now have a good understanding of the role of miR-133 during cardiac hypertrophy, the full range of targets that mediate its effects remain to be identified and characterized. One of the reasons that miRNAs may potentially serve as more effective therapeutic targets is their capacity to regulate an array of genes, which collaborate in a particular cellular function, versus a single gene. Thus, to fully exploit miRNAs for therapeutic purposes, it is necessary not only to identify and validate all targets but also to examine their functional interactions.11Table 2. Non-standard AbbreviationmiRNAmicroRNAThe opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.Sources of FundingSupported by NIH grants 2R01 HL057970 and R01 HL081381.DisclosuresNone.FootnotesCorrespondence to Maha Abdellatif, Cardiovascular Research Institute, Department of Cell Biology and Molecular Medicine, University of Medicine and Dentistry of New Jersey, Newark, NJ 07103. E-mail [email protected] References 1 Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75: 843–854.CrossrefMedlineGoogle Scholar2 Ivey KN, Muth A, Arnold J, King FW, Yeh RF, Fish JE, Hsiao EC, Schwartz RJ, Conklin BR, Bernstein HS, Srivastava D. MicroRNA regulation of cell lineages in mouse and human embryonic stem cells. Cell Stem Cell. 2008; 2: 219–229.CrossrefMedlineGoogle Scholar3 Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL, Wang DZ. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet. 2006; 38: 228–233.CrossrefMedlineGoogle Scholar4 Liu N, Bezprozvannaya S, Williams AH, Qi X, Richardson JA, Bassel-Duby R, Olson EN. MicroRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev. 2008; 22: 3242–3254.CrossrefMedlineGoogle Scholar5 van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA, Olson EN. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A. 2006; 103: 18255–18260.CrossrefMedlineGoogle Scholar6 Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini P, Gu Y, Dalton ND, Elia L, Latronico MV, Hoydal M, Autore C, Russo MA, Dorn GW II, Ellingsen O, Ruiz-Lozano P, Peterson KL, Croce CM, Peschle C, Condorelli G. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007; 13: 613–618.CrossrefMedlineGoogle Scholar7 Cheng Y, Ji R, Yue J, Yang J, Liu X, Chen H, Dean DB, Zhang C. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol. 2007; 170: 1831–1840.CrossrefMedlineGoogle Scholar8 Matkovich SJ, Wang W, Tu Y, Eschenbacher WH, Dorn LE, Condorelli G, Diwan A, Nerbonne JM, Dorn GW II. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res. 2010; 106: 166–175.LinkGoogle Scholar9 Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I, Herias V, van Leeuwen RE, Schellings MW, Barenbrug P, Maessen JG, Heymans S, Pinto YM, Creemers EE. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res. 2009; 104: 170–178.LinkGoogle Scholar10 Xu C, Lu Y, Pan Z, Chu W, Luo X, Lin H, Xiao J, Shan H, Wang Z, Yang B. The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci. 2007; 120: 3045–3052.CrossrefMedlineGoogle Scholar11 Rane S, He M, Sayed D, Vashistha H, Malhotra A, Sadoshima J, Vatner DE, Vatner SF, Abdellatif M. Downregulation of miR-199a derepresses hypoxia-inducible factor-1{alpha} and sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res. 2009; 104: 879–886.LinkGoogle Scholar12 Xiao J, Luo X, Lin H, Zhang Y, Lu Y, Wang N, Zhang Y, Yang B, Wang Z. MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts. J Biol Chem. 2007; 282: 12363–12367.CrossrefMedlineGoogle Scholar13 Luo X, Lin H, Pan Z, Xiao J, Zhang Y, Lu Y, Yang B, Wang Z. Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. J Biol Chem. 2008; 283: 20045–20052.CrossrefMedlineGoogle Scholar14 Li Z, Hassan MQ, Volinia S, van Wijnen AJ, Stein JL, Croce CM, Lian JB, Stein GS. A microRNA signature for a BMP2-induced osteoblast lineage commitment program. Proc Natl Acad Sci U S A. 2008; 105: 13906–13911.CrossrefMedlineGoogle Scholar15 Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV, Murchison E, Hannon G, Abeliovich A. A MicroRNA feedback circuit in midbrain dopamine neurons. Science. 2007; 317: 1220–1224.CrossrefMedlineGoogle Scholar16 Yin VP, Thomson JM, Thummel R, Hyde DR, Hammond SM, Poss KD. Fgf-dependent depletion of microRNA-133 promotes appendage regeneration in zebrafish. Genes Dev. 2008; 22: 728–733.CrossrefMedlineGoogle Scholar17 Crawford M, Batte K, Yu L, Wu X, Nuovo GJ, Marsh CB, Otterson GA, Nana-Sinkam SP. MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem Biophys Res Commun. 2009; 388: 483–489.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Pirola L, Ciesielski O, Biesiekierska M and Balcerczyk A (2021) Modulation of noncoding RNAs (ncRNAs) and their potential role as therapeutics Medical Epigenetics, 10.1016/B978-0-12-823928-5.00041-4, (721-740), . Ghosh A, Platt R, Vandewege M, Tabassum R, Hsu C, Isberg S, Peterson D, Finger J, Kieran T, Glenn T, Gongora J and Ray D (2020) Identification and characterization of microRNAs (miRNAs) and their transposable element origins in the saltwater crocodile, Crocodylus porosus, Analytical Biochemistry, 10.1016/j.ab.2020.113781, 602, (113781), Online publication date: 1-Aug-2020. Chen H, Lou L, Zhang D, Zhao Y, Zhao J, Li C, Huang Y, Liu K, Zhao M and Wu A (2019) Qiliqiangxin Capsule Improves Cardiac Function and Attenuates Cardiac Remodeling by Upregulating miR-133a after Myocardial Infarction in Rats, Evidence-Based Complementary and Alternative Medicine, 10.1155/2019/7528214, 2019, (1-9), Online publication date: 14-Mar-2019. Jie H, Zhang P, Xu Z, Mishra S, Lei M, Zeng D, Zhao G and Li D (2019) microRNA and Other Small RNA Sequence Profiling across Six Tissues of Chinese Forest Musk Deer ( Moschus berezovskii ) , BioMed Research International, 10.1155/2019/4370704, 2019, (1-9), Online publication date: 12-May-2019. Bhattacharya M, Ghosh S, Malick R, Patra B and Das B (2018) Therapeutic applications of zebrafish (Danio rerio) miRNAs linked with human diseases: A prospective review, Gene, 10.1016/j.gene.2018.09.008, 679, (202-211), Online publication date: 1-Dec-2018. Danese E, Benati M, Sanchis-Gomar F, Tarperi C, Salvagno G, Paviati E, Montagnana M, Schena F and Lippi G (2018) Influence of middle-distance running on muscular micro RNAs, Scandinavian Journal of Clinical and Laboratory Investigation, 10.1080/00365513.2018.1426104, 78:3, (165-170), Online publication date: 3-Apr-2018. Aslibekyan S, Claas S and Arnett D (2017) Epigenetics in Cardiovascular Disease Translating Epigenetics to the Clinic, 10.1016/B978-0-12-800802-7.00006-X, (135-157), . Zou X, Liu T, Gong Z, Hu C and Zhang Z (2017) MicroRNAs-mediated epithelial-mesenchymal transition in fibrotic diseases, European Journal of Pharmacology, 10.1016/j.ejphar.2016.12.003, 796, (190-206), Online publication date: 1-Feb-2017. Bartczak A, McGilvray I and Keating A (2017) Mesenchymal stromal cell therapy to promote cardiac tissue regeneration and repair, Current Opinion in Organ Transplantation, 10.1097/MOT.0000000000000379, 22:1, (86-96), Online publication date: 1-Feb-2017. Biglino G, Caputo M, Rajakaruna C, Angelini G, van Rooij E and Emanueli C (2017) Modulating microRNAs in cardiac surgery patients: Novel therapeutic opportunities?, Pharmacology & Therapeutics, 10.1016/j.pharmthera.2016.11.004, 170, (192-204), Online publication date: 1-Feb-2017. Ke-Gang J, Zhi-Wei L, Xin Z, Jing W, Ping S, Xue-Jing H, Hong-Xia T, Xin T and Xiao-Cheng L (2016) Evaluating Diagnostic and Prognostic Value of Plasma miRNA133a in Acute Chest Pain Patients Undergoing Coronary Angiography, Medicine, 10.1097/MD.0000000000003412, 95:17, (e3412), Online publication date: 1-Apr-2016. Chistiakov D, Orekhov A and Bobryshev Y (2016) Cardiac-specific miRNA in cardiogenesis, heart function, and cardiac pathology (with focus on myocardial infarction), Journal of Molecular and Cellular Cardiology, 10.1016/j.yjmcc.2016.03.015, 94, (107-121), Online publication date: 1-May-2016. Lu M, Zhang P, Li C, Lv Z, Zhang W and Jin C (2015) miRNA-133 augments coelomocyte phagocytosis in bacteria-challenged Apostichopus japonicus via targeting the TLR component of IRAK-1 in vitro and in vivo, Scientific Reports, 10.1038/srep12608, 5:1, Online publication date: 1-Dec-2015. Diniz G, Lino C, Guedes E, Nascimento Moreira L and Barreto-Chaves M (2015) Cardiac microRNA-133 is down-regulated in thyroid hormone-mediated cardiac hypertrophy partially via Type 1 Angiotensin II receptor, Basic Research in Cardiology, 10.1007/s00395-015-0504-7, 110:5, Online publication date: 1-Sep-2015. Rajan K, Velmurugan G, Pandi G and Ramasamy S (2014) miRNA and piRNA mediated Akt pathway in heart: Antisense expands to survive, The International Journal of Biochemistry & Cell Biology, 10.1016/j.biocel.2014.09.001, 55, (153-156), Online publication date: 1-Oct-2014. Chen S, Puthanveetil P, Feng B, Matkovich S, Dorn G and Chakrabarti S (2014) Cardiac miR‐133a overexpression prevents early cardiac fibrosis in diabetes, Journal of Cellular and Molecular Medicine, 10.1111/jcmm.12218, 18:3, (415-421), Online publication date: 1-Mar-2014. Nair R, Santos L, Awasthi S, von Erlach T, Chow L, Bertazzo S and Stevens M (2014) Extracellular Vesicles Derived from Preosteoblasts Influence Embryonic Stem Cell Differentiation, Stem Cells and Development, 10.1089/scd.2013.0633, 23:14, (1625-1635), Online publication date: 15-Jul-2014. Kishore A, Borucka J, Petrkova J and Petrek M (2014) Novel Insights into miRNA in Lung and Heart Inflammatory Diseases, Mediators of Inflammation, 10.1155/2014/259131, 2014, (1-27), . Espinoza-Lewis R and Wang D (2012) MicroRNAs in Heart Development Heart Development, 10.1016/B978-0-12-387786-4.00009-9, (279-317), . Matkovich S, Van Booven D, Eschenbacher W and Dorn G (2010) RISC RNA Sequencing for Context-Specific Identification of In Vivo MicroRNA Targets, Circulation Research, 108:1, (18-26), Online publication date: 7-Jan-2011. Ha T (2011) MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease, Immune Network, 10.4110/in.2011.11.3.135, 11:3, (135), . Xu Z, Sun J, Tong Q, Lin Q, Qian L, Park Y and Zheng Y (2016) The Role of ERK1/2 in the Development of Diabetic Cardiomyopathy, International Journal of Molecular Sciences, 10.3390/ijms17122001, 17:12, (2001) Laganà A, Veneziano D, Spata T, Tang R, Zhu H, Mohler P, Kilic A and Pignataro G (2015) Identification of General and Heart-Specific miRNAs in Sheep (Ovis aries), PLOS ONE, 10.1371/journal.pone.0143313, 10:11, (e0143313) Tapia-Castillo A, Carvajal C, Pérez J and Fardella C (2022) Clinical, biochemical, and miRNA profile of subjects with positive screening of primary aldosteronism and nonclassic apparent mineralocorticoid excess, Endocrine, 10.1007/s12020-022-03103-x Mir R, Elfaki I, Khullar N, Waza A, Jha C, Mir M, Nisa S, Mohammad B, Mir T, Maqbool M, Barnawi J, Albalawi S and Abu-Duhier F (2021) Role of Selected miRNAs as Diagnostic and Prognostic Biomarkers in Cardiovascular Diseases, Including Coronary Artery Disease, Myocardial Infarction and Atherosclerosis, Journal of Cardiovascular Development and Disease, 10.3390/jcdd8020022, 8:2, (22) Singh G and Storey K (2021) MicroRNA Cues from Nature: A Roadmap to Decipher and Combat Challenges in Human Health and Disease?, Cells, 10.3390/cells10123374, 10:12, (3374) Biswas S and Chakrabarti S (2019) Increased Extracellular Matrix Protein Production in Chronic Diabetic Complications: Implications of Non-Coding RNAs, Non-Coding RNA, 10.3390/ncrna5010030, 5:1, (30) Jiang F, Zhou X, Huang J and Fan G (2016) Long Non-Coding RNA-ROR Mediates the Reprogramming in Cardiac Hypertrophy, PLOS ONE, 10.1371/journal.pone.0152767, 11:4, (e0152767) Zhang Y, Lai Y, Zhou X and Zhu F (2022) The Role of microRNA-133 in Hemocyte Proliferation and Innate Immunity of Scylla paramamosain, Frontiers in Immunology, 10.3389/fimmu.2021.812717, 12 Zhao H, Li M, Li L, Yang X, Lan G, Zhang Y and Kyprianou N (2013) MiR-133b Is Down-Regulated in Human Osteosarcoma and Inhibits Osteosarcoma Cells Proliferation, Migration and Invasion, and Promotes Apoptosis, PLoS ONE, 10.1371/journal.pone.0083571, 8:12, (e83571) Adamcova M, Kawano I and Simko F (2021) The Impact of microRNAs in Renin–Angiotensin-System-Induced Cardiac Remodelling, International Journal of Molecular Sciences, 10.3390/ijms22094762, 22:9, (4762) Palabiyik O, Tastekin E, Doganlar Z, Tayfur P, Dogan A and Vardar S (2018) Alteration in cardiac PI3K/Akt/mTOR and ERK signaling pathways with the use of growth hormone and swimming, and the roles of miR21 and miR133, Biomedical Reports, 10.3892/br.2018.1179 Kastner N, Zlabinger K, Spannbauer A, Traxler D, Mester-Tonczar J, Hašimbegović E and Gyöngyösi M (2020) New Insights and Current Approaches in Cardiac Hypertrophy Cell Culture, Tissue Engineering Models, and Novel Pathways Involving Non-Coding RNA, Frontiers in Pharmacology, 10.3389/fphar.2020.01314, 11 Scărlătescu A, Micheu M, Popa-Fotea N and Dorobanțu M (2021) MicroRNAs in Acute ST Elevation Myocardial Infarction—A New Tool for Diagnosis and Prognosis: Therapeutic Implications, International Journal of Molecular Sciences, 10.3390/ijms22094799, 22:9, (4799) January 8, 2010Vol 106, Issue 1 Advertisement Article InformationMetrics https://doi.org/10.1161/CIRCRESAHA.109.212183PMID: 20056941 Originally publishedJanuary 8, 2010 KeywordsmiR-133K+ channelfibrosishypertrophyapoptosisPDF download Advertisement
Referência(s)